S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
NASDAQ:AMRS

Amyris - AMRS Stock Forecast, Price & News

$1.60
+0.04 (+2.56%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.52
$1.64
50-Day Range
$1.38
$2.23
52-Week Range
$1.25
$5.31
Volume
3.91 million shs
Average Volume
5.32 million shs
Market Capitalization
$528.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.67

Amyris MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
191.7% Upside
$4.67 Price Target
Short Interest
Bearish
21.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.50mentions of Amyris in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.57) to ($0.66) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Basic Materials Sector

101st out of 161 stocks

Industrial Organic Chemicals Industry

10th out of 20 stocks


AMRS stock logo

About Amyris (NASDAQ:AMRS) Stock

Amyris, Inc. engages in the provision of bioscience solutions. It offers its products to the health and wellness, clean beauty, and flavor and fragrance markets. The company was founded by Jack D. Newman, Kinkead Keith Reiling, and Neil Renninger on July 17, 2003 and is headquartered in Emeryville, CA.

Receive AMRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amyris and its competitors with MarketBeat's FREE daily newsletter.

AMRS Stock News Headlines

Amyris (NASDAQ:AMRS) Trading 5.4% Higher
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
AMYRIS SUCCESSFULLY ADVANCES STRATEGIC TRANSACTION
10 Cheap Small-Cap Stocks to Buy Before the Next Breakout
Why Amyris Stock Was Driven Into the Ground on Wednesday
AMYRIS, INC. REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
AMYRIS SUCCESSFULLY LAUNCHES TWO NEW CONSUMER BRANDS
See More Headlines
Receive AMRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amyris and its competitors with MarketBeat's FREE daily newsletter.

AMRS Company Calendar

Last Earnings
11/08/2022
Today
1/28/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Industrial organic chemicals
Sub-Industry
Oil & Gas Refining & Marketing
Current Symbol
NASDAQ:AMRS
CUSIP
03236M10
Employees
980
Year Founded
2003

Price Target and Rating

Average Stock Price Forecast
$4.67
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+191.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Net Income
$-270,970,000.00
Net Margins
-131.70%
Pretax Margin
-135.65%

Debt

Sales & Book Value

Annual Sales
$341.82 million
Book Value
$0.80 per share

Miscellaneous

Free Float
218,565,000
Market Cap
$528.26 million
Optionable
Optionable
Beta
1.11

Social Links


Key Executives

  • John G. MeloJohn G. Melo
    President, Chief Executive Officer & Director
  • Eduardo AlvarezEduardo Alvarez
    Chief Operating Officer
  • Han Kieftenbeld
    Chief Financial & Administration Officer
  • Sunil Chandran
    Senior Vice President-Research & Development
  • Charles Kraft
    SVP-Global Manufacturing & Process Development













AMRS Stock - Frequently Asked Questions

Should I buy or sell Amyris stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AMRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMRS, but not buy additional shares or sell existing shares.
View AMRS analyst ratings
or view top-rated stocks.

What is Amyris' stock price forecast for 2023?

4 equities research analysts have issued twelve-month target prices for Amyris' stock. Their AMRS share price forecasts range from $2.00 to $6.00. On average, they predict the company's stock price to reach $4.67 in the next twelve months. This suggests a possible upside of 191.7% from the stock's current price.
View analysts price targets for AMRS
or view top-rated stocks among Wall Street analysts.

How have AMRS shares performed in 2023?

Amyris' stock was trading at $1.53 at the beginning of 2023. Since then, AMRS stock has increased by 4.6% and is now trading at $1.60.
View the best growth stocks for 2023 here
.

When is Amyris' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our AMRS earnings forecast
.

How were Amyris' earnings last quarter?

Amyris, Inc. (NASDAQ:AMRS) issued its quarterly earnings results on Tuesday, November, 8th. The biotechnology company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.25. The biotechnology company earned $71.13 million during the quarter, compared to analysts' expectations of $111.98 million.

When did Amyris' stock split?

Amyris's stock reverse split on the morning of Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What guidance has Amyris issued on next quarter's earnings?

Amyris issued an update on its fourth quarter 2022 earnings guidance on Thursday, December, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $100.00M-, compared to the consensus revenue estimate of $138.39 million.

What is John Melo's approval rating as Amyris' CEO?

84 employees have rated Amyris Chief Executive Officer John Melo on Glassdoor.com. John Melo has an approval rating of 54% among the company's employees. This puts John Melo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 77.0% of employees surveyed would recommend working at Amyris to a friend.

What other stocks do shareholders of Amyris own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Nokia Oyj (NOK), Gevo (GEVO), Inovio Pharmaceuticals (INO), Pfizer (PFE), AT&T (T), Dynavax Technologies (DVAX), Novavax (NVAX) and NVIDIA (NVDA).

What is Amyris' stock symbol?

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

Who are Amyris' major shareholders?

Amyris' stock is owned by a variety of retail and institutional investors. Top institutional investors include State of Michigan Retirement System (2.32%), Pinnacle Associates Ltd. (1.26%), Wealth Alliance Advisory Group LLC (0.01%) and National Bank of Canada FI (0.00%). Insiders that own company stock include Anthony Hughes, Eduardo Alvarez, Frank Kung, Hermanus Kieftenbeld, James F Mccann, John Melo, L John Doerr and Nicole Kelsey.
View institutional ownership trends
.

How do I buy shares of Amyris?

Shares of AMRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amyris' stock price today?

One share of AMRS stock can currently be purchased for approximately $1.60.

How much money does Amyris make?

Amyris (NASDAQ:AMRS) has a market capitalization of $528.26 million and generates $341.82 million in revenue each year. The biotechnology company earns $-270,970,000.00 in net income (profit) each year or ($1.74) on an earnings per share basis.

How many employees does Amyris have?

The company employs 980 workers across the globe.

How can I contact Amyris?

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The official website for the company is amyris.com. The biotechnology company can be reached via phone at (510) 450-0761, via email at investor@amyris.com, or via fax at 510-225-2645.

This page (NASDAQ:AMRS) was last updated on 1/28/2023 by MarketBeat.com Staff